Your AI-Trained Oncology Knowledge Connection!
MONTREAL, Canada--Tomudex (ZD1694), a new direct and specific thymidylate synthase (TS) inhibitor, has been shown to be especially promising for the treatment of patients with advanced colorectal cancer, David Cunningham, MD, said at the 19th International Congress of Chemotherapy.
PARIS, France--Biochemical modulators have brightened the prospects for patients with advanced gastrointestinal cancer, Scott Wadler, MD, reported at the American Radium Society annual meeting.
BOSTON--A radiolabeled monoclonal antibody (MoAb) currently under investigation may improve detection of recurrent colorectal cancer, said Dr. Frederick Moffat, associate professor of surgery, University of Miami Medical School.
Intraoperative radiation therapy (IORT) has the obvious advantage of maximally irradiating the tumor bed while eliminating surrounding normal organs from the field of radiation. This approach has been especially useful when the required radiation dose exceeds the tolerance dose of the surrounding normal tissues. However, the application of IORT has been significantly limited by cost, logistic issues, and technical problems related to delivering treatment to difficult anatomic areas. We have developed a new approach to IORT that obviates the need for patient transport: In a dedicated, shielded operating room, the surgery is performed and IORT is delivered via HDR remote afterloading. We have found this approach to be cost effective, logistically sound, and suitable for a wide range of anatomic sites. The technical aspects of the procedure, as well our preliminary results in colorectal cancer, will be presented. Lastly, the authors present the technical aspects of delivering HDR intraoperative brachytherapy, their dosimetry atlas, and their results using HDR-IORT in the treatment of patients with colorectal cancer[ONCOLOGY 9(7):679-683, 1995]
FORT LAUDERDALE, Fla--Because colon cancer develops in a stepwise progression that occurs over 10 to 15 years, physicians have a "tremendous window of opportunity for prevention," Sidney Winawer, MD, of Memorial Sloan-Kettering Cancer Center, said in a presentation at the second annual Industries' Coalition Against Cancer (ICAC) conference. He believes that colorectal cancer screening is "no longer controversial," based on available data.
The authors have nicely reviewed many of the issues surrounding laparoscopic colon cancer surgery. However, we would like to offer a slightly different perspective on several points which they make.
INDIANAPOLIS--Eli Lilly and Company has received FDA approval to provide gemcitabine (Gemzar) to advanced pancreatic cancer patients through a Treatment Investigational New Drug program.
LISBON, Portugal--Although folinic acid and interferon have been shown to heighten the efficacy of 5-fluorouracil (5-FU) in colorectal cancer, the ability of these biochemical modulators to prolong survival is less certain. Now a prospective randomized trial conducted in Germany has revealed that patients with advanced, symptomatic colorectal cancer who are treated with 5-FU and folinic acid live longer and have a better quality of life than do those who receive 5-FU and interferon.
Carcinoma of the gallbladder is a rare malignancy, with an incidence rate in the United States of 2.2 to 4.4 per 100,000 persons. Its clinical presentation is nonspecific, and the majority of patients have advanced disease at
